Biogen Inc (BIIB) : Old Mutual Global Investors (uk) Ltd. scooped up 104,178 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 22, 2016. The investment management firm now holds a total of 422,292 shares of Biogen Inc which is valued at $121,527,192.Biogen Inc makes up approximately 2.17% of Old Mutual Global Investors (uk) Ltd.’s portfolio.
Other Hedge Funds, Including , Meeder Asset Management Inc boosted its stake in BIIB in the latest quarter, The investment management firm added 619 additional shares and now holds a total of 6,433 shares of Biogen Inc which is valued at $1,851,289. Biogen Inc makes up approx 0.17% of Meeder Asset Management Inc’s portfolio. Horan Capital Management added BIIB to its portfolio by purchasing 4,295 company shares during the most recent quarter which is valued at $1,236,015. Biogen Inc makes up approx 0.33% of Horan Capital Management’s portfolio. Quantres Asset Management Ltd added BIIB to its portfolio by purchasing 10,400 company shares during the most recent quarter which is valued at $2,992,912. Biogen Inc makes up approx 1.78% of Quantres Asset Management Ltd’s portfolio. Trust Department Mb Financial Bank N A added BIIB to its portfolio by purchasing 19,164 company shares during the most recent quarter which is valued at $5,011,386. Biogen Inc makes up approx 0.54% of Trust Department Mb Financial Bank N A’s portfolio.Gateway Investment Advisers boosted its stake in BIIB in the latest quarter, The investment management firm added 957 additional shares and now holds a total of 173,476 shares of Biogen Inc which is valued at $43,575,436. Biogen Inc makes up approx 0.37% of Gateway Investment Advisers’s portfolio.
Biogen Inc opened for trading at $288.85 and hit $290.46 on the upside on Friday, eventually ending the session at $289.93, with a gain of 0.31% or 0.9 points. The heightened volatility saw the trading volume jump to 13,38,487 shares. Company has a market cap of $63,530 M.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.